If you’ve had a small polyp removed during a colonoscopy, you may have been told to come back in three to five years. A growing body of evidence suggests that for low-risk cases, that’s often sooner than necessary — and that waiting longer is safe.
Some background on polyps and surveillance
During a colonoscopy, doctors often find and remove adenomas — small growths that can, over many years, occasionally turn into colorectal cancer. Removing them is a cornerstone of cancer prevention. Afterward, patients are placed on a surveillance schedule for repeat colonoscopies. But not all polyps carry the same risk: people with one or two small (under 10 mm) tubular adenomas without worrisome features are considered low risk, with a colorectal cancer risk only marginally above average and well below that of high-risk patients.
What the evidence shows
Recent studies support longer intervals for these low-risk patients. In one 2026 analysis, extending surveillance to seven years or more among people with one or two small, low-risk adenomas did not significantly increase the detection of concerning polyps compared with earlier follow-up. Current U.S. guidelines already recommend repeat colonoscopy in seven to ten years for such patients — yet in practice, many are still brought back every three to five years, more often than the evidence supports.
Why over-scoping is a problem
Colonoscopy is safe and valuable, but it is not free of downsides: it requires an unpleasant bowel prep, carries small procedural risks, costs money and consumes limited capacity. Every unnecessary surveillance colonoscopy for a low-risk patient is a slot that could go to someone overdue for screening or genuinely high-risk. Right-sizing intervals is therefore about both patient burden and system efficiency — doing fewer procedures where they add little, so resources flow to where they matter.
Why it matters
The message is not “skip screening” — colorectal cancer screening saves lives, and staying on schedule is important. The point is that the right interval depends on risk, and for genuinely low-risk patients, a longer gap is evidence-based, not corner-cutting. Aligning practice with guidelines could spare many people procedures they don’t need.
The caveats
This applies specifically to low-risk findings; people with larger polyps, multiple polyps, advanced features, a family history or other risk factors need closer surveillance, and undertreating them would be dangerous. Guidelines also evolve, and individual circumstances vary. The right schedule is a decision to make with your gastroenterologist, based on your specific results. This summarizes research and is not medical advice.